Investing.com - Can Fite Biopharma ADR reported on Thursday fourth quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
Can Fite Biopharma ADR announced earnings per share of $-0.18 on revenue of $275K. Analysts polled by Investing.com anticipated EPS of $-0.165 on revenue of $275K.
Can Fite Biopharma ADR shares are down 16.51% from the beginning of the year, still down 58.89% from its 52 week high of $2.62 set on June 15, 2021. They are under-performing the EUR/USD which is down 0% from the start of the year.
Can Fite Biopharma ADR shares gained 5.54% in intra-day trade following the report.
Can Fite Biopharma ADR follows other major Healthcare sector earnings this month
Can Fite Biopharma ADR's report follows an earnings missed by Merck ADR on March 3, who reported EPS of $0.4558 on revenue of $5.77B, compared to forecasts EPS of $0.4818 on revenue of $5.88B.
Moderna had beat expectations on February 24 with fourth quarter EPS of $11.29 on revenue of $7.21B, compared to forecast for EPS of $9.96 on revenue of $6.8B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar